Alberto Fusi

3.2k total citations
53 papers, 1.5k citations indexed

About

Alberto Fusi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Alberto Fusi has authored 53 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Oncology, 18 papers in Pulmonary and Respiratory Medicine and 17 papers in Molecular Biology. Recurrent topics in Alberto Fusi's work include Immunotherapy and Immune Responses (13 papers), Melanoma and MAPK Pathways (10 papers) and Lung Cancer Treatments and Mutations (10 papers). Alberto Fusi is often cited by papers focused on Immunotherapy and Immune Responses (13 papers), Melanoma and MAPK Pathways (10 papers) and Lung Cancer Treatments and Mutations (10 papers). Alberto Fusi collaborates with scholars based in Germany, United Kingdom and Italy. Alberto Fusi's co-authors include Ulrich Keilholz, Paul Lorigan, Anika Nonnenmacher, Caroline Dive, Antonia Busse, Ingeborg Tinhofer, Sebastian Ochsenreither, Zhian Liu, Alexander Schmittel and Fiona Blackhall and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and Clinical Cancer Research.

In The Last Decade

Alberto Fusi

51 papers receiving 1.5k citations

Peers

Countries citing papers authored by Alberto Fusi

Since Specialization

Citations

This map shows the geographic impact of Alberto Fusi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alberto Fusi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alberto Fusi more than expected).

Fields of papers citing papers by Alberto Fusi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alberto Fusi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alberto Fusi. The network helps show where Alberto Fusi may publish in the future.

Co-authorship network of co-authors of Alberto Fusi

This figure shows the co-authorship network connecting the top 25 collaborators of Alberto Fusi. A scholar is included among the top collaborators of Alberto Fusi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alberto Fusi. Alberto Fusi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	1111P A randomised phase II study of intermittent versus continuous dosing of targeted therapy in patients with BRAFV600 mutant advanced melanoma (INTERIM) 2023 ·Annals of Oncology ·Avinash Gupta, Rubeta Matin, Alimu Dayimu, Jenny Nobes, Ruth Board, Miranda Payne, Ankit Rao, Alberto Fusi, Sarah Danson, Bryony Eccles, Judith Carser, (unknown), Neil Steven, George J. Burghel, Leigh Demain, (unknown), Jerome Wulff, Sophie Twelves, Mark R. Middleton, Pippa Corrie	0
2	Enhanced effect of checkpoint inhibitors when given after or together with IMM-101: significant responses in four advanced melanoma patients with no additional major toxicity 2018 ·Journal of Translational Medicine ·Angus Dalgleish, Satvinder Mudan, Alberto Fusi	13
3	A phase I dose escalation study of the tolerability of the oral VEGFR and EGFR inhibitor vandetanib in combination with the oral MEK1/2 inhibitor selumetinib in solid tumors 2016 ·Annals of Oncology ·Simon Pacey, Fiona Blackhall, Javier García-Corbacho, (unknown), Alberto Fusi, Sanjeev Kumar, (unknown), (unknown), (unknown), Sarah Halford, (unknown), (unknown), Susan Wan, Denis Talbot	1
4	Distinct subclonal tumour responses to therapy revealed by circulating cell-free DNA 2016 ·Annals of Oncology ·Gabriela Gremel, Rebecca Lee, María Romina Girotti, Amit Kumar Mandal, Sara Valpione, Grace Garner, Mahmood Ayub, S. Wood, Dominic G. Rothwell, Alberto Fusi, Andrea Wallace, Gerard Brady, Caroline Dive, Nathalie Dhomen, Paul Lorigan, Richard Marais	46
5	Optimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer 2015 ·Lung Cancer ·M. Howell, Rebecca Lee, Samantha Bowyer, Alberto Fusi, Paul Lorigan	40
6	Circulating tumour cells as tumour biomarkers in melanoma: detection methods and clinical relevance 2014 ·Annals of Oncology ·Leila Khoja, Paul Lorigan, Caroline Dive, Ulrich Keilholz, Alberto Fusi	54
7	Activity of the Monocarboxylate Transporter 1 Inhibitor AZD3965 in Small Cell Lung Cancer 2013 ·Clinical Cancer Research ·Radosław Polański, Cassandra L. Hodgkinson, Alberto Fusi, Daisuke Nonaka, Lynsey Priest, Paul A. Kelly, Francesca Trapani, Paul Bishop, Anne White, Susan E. Critchlow, Paul D. Smith, Fiona Blackhall, Caroline Dive, Christopher J. Morrow	282
8	Clinical Utility of Circulating Tumour Cell Detection in Non-Small-Cell Lung Cancer 2013 ·Current Treatment Options in Oncology ·Alberto Fusi, Robert Metcalf, Matthew Krebs, Caroline Dive, Fiona Blackhall	18
9	Analysis of surrogate gene expression markers in peripheral blood of melanoma patients to predict treatment outcome of adjuvant pegylated interferon alpha 2b (EORTC 18991 side study) 2013 ·Cancer Immunology Immunotherapy ·Antonia Busse, Jérôme Rapion, Alberto Fusi, Stefan Suciu, Anika Nonnenmacher, Mario Santinami, Wim H.J. Kruit, Alessandro Testori, Cornelis J.A. Punt, Angus Dalgleish, Alan Spatz, Alexander Eggermont, Ulrich Keilholz	5
10	The presence of circulating tumor cells (CTCs) correlates with lymph node metastasis in nonresectable squamous cell carcinoma of the head and neck region (SCCHN) 2011 ·Annals of Oncology ·(unknown), Robert Konschak, Carmen Stromberger, Alberto Fusi, Zhou Liu, Wilko Weichert, Albrecht Stenzinger, Volker Budach, Ulrich Keilholz, Ingeborg Tinhofer	107
11	Immunomodulatory effects of sorafenib on peripheral immune effector cells in metastatic renal cell carcinoma 2011 ·European Journal of Cancer ·Antonia Busse, Anne Marie Asemissen, Anika Nonnenmacher, (unknown), Sebastian Ochsenreither, David R. Stather, Alberto Fusi, Alexander Schmittel, Kurt Miller, Eckhard Thiel, Ulrich Keilholz	53
12	Enhanced detection of BRAF-mutants by pre-PCR cleavage of wild-type sequences revealed circulating melanoma cells heterogeneity 2011 ·European Journal of Cancer ·Alberto Fusi, (unknown), (unknown), Anika Nonnenmacher, Ulrich Keilholz	10
13	Wilms' tumor protein 1 (WT1) peptide vaccination in AML patients: predominant TCR CDR3β sequence associated with remission in one patient is detectable in other vaccinated patients 2011 ·Cancer Immunology Immunotherapy ·Sebastian Ochsenreither, Alberto Fusi, (unknown), David R. Stather, Antonia Busse, Andrea Stroux, Anne Letsch, Ulrich Keilholz	15
14	Comparison of T-cell receptor repertoire restriction in blood and tumor tissue of colorectal cancer patients 2010 ·Journal of Translational Medicine ·Sebastian Ochsenreither, Alberto Fusi, (unknown), Antonia Busse, Natascha C. Nüssler, Eckhard Thiel, Ulrich Keilholz, Dirk Nagorsen	12
15	Expression of the stem cell marker nestin in peripheral blood of patients with melanoma 2010 ·British Journal of Dermatology ·Alberto Fusi, Sebastian Ochsenreither, Antonia Busse, A. Rietz, Ulrich Keilholz	26
16	Long term presence of a single predominant tyrosinase‐specific T‐cell clone associated with disease control in a patient with metastatic melanoma 2009 ·International Journal of Cancer ·Sebastian Ochsenreither, Alberto Fusi, Antonia Busse, Anne Letsch, Doreen Haase, Eckhard Thiel, Carmen Scheibenbogen, Ulrich Keilholz	5
17	Relative quantification of TCR Vbeta-chain families by real time PCR for identification of clonal T-cell populations 2008 ·Journal of Translational Medicine ·Sebastian Ochsenreither, Alberto Fusi, Antonia Busse, Dirk Nagorsen, David Schrama, Jürgen C. Becker, Eckhard Thiel, Ulrich Keilholz	21
18	Is Irinotecan Plus Docetaxel Useful as Second-Line Therapy in Advanced Non-small Cell Lung Cancer? 2008 ·Journal of Thoracic Oncology ·Diego Cortinovis, Paolo Bidoli, Daniela Cullurà, Vito Lorusso, Antonio Ardizzoia, Vito Amoroso, M. Bandera, Enrico Aitini, Alberto Fusi, Nicoletta Zilembo, (unknown), Emilio Bajetta	2
19	Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-α2b in metastatic melanoma 2006 ·Annals of Oncology ·E. Bajetta, Michele Del Vecchio, (unknown), Alberto Fusi, Antonio Daponte, M.R. Sertoli, Paola Queirolo, (unknown), Maria Grazia Bernengo, Sewa S. Legha, Barbara Formisano, N. Cascinelli	83
20	Treatment Options in Hormone-refractory Metastatic Prostate Carcinoma 2004 ·Tumori Journal ·Alberto Fusi, Giuseppe Procopio, S. Della Torre, Riccardo Ricotta, Giampaolo Bianchini, Roberto Salvioni, (unknown), Antonia Martinetti, Giordano Savelli, S. Villà, Emilio Bajetta	31

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact